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Background: Active immunization against Aβ was reported to have a therapeutic effect in murine models of
Alzheimer’s disease. Clinical Aβ vaccination trial AN1792 was interrupted due to the development in 6 % of the
patients of meningoencephalitis likely involving pro-inflammatory CD4+ T cells. However, the potential implication
of auto-aggressive anti-Aβ CD8+ T cells has been poorly investigated.
Methods: Potential MHC-I-restricted Aβ-derived epitopes were first analyzed for their capacity to recruit functional
CD8+ T cell responses in mouse models. Their impact on migration of CD8+ T cells into the brain parenchyma and
potential induction of meningoencephalitis and/or neuronal damage was investigated upon vaccination in the
APPPS1 mouse model of AD.
Results: We identified one nonamer peptide, Aβ33-41, which was naturally processed and presented in association
with H-2-Db molecule on neurons and CD11b+ microglia. Upon optimization of anchor residues for enhanced binding
to H-2-Db, immunization with the modified Aβ33-41NP peptide elicited Aβ-specific IFNγ-secreting CD8+ T cells, which
are cytotoxic towards Aβ-expressing targets. Whereas T cell infiltration in the brain of APPPS1 mice is dominated by
CD3+CD8− T cells and increases with disease evolution between 4 and 7 months of age, a predominance of CD3+CD8+
over CD3+CD8− cells was observed in 6- to 7-month-old APPPS1 but not in WT animals, only after vaccination with
Aβ33-41NP. The number of CD11b+ mononuclear phagocytes, which significantly increases with age in the brain of
APPPS1 mice, was reduced following immunization with Aβ33-41NP. Despite peripheral activation of Aβ-specific CD8+
cytotoxic effectors and enhanced infiltration of CD8+ T cells in the brain of Aβ33-41NP-immunized APPPS1 mice, no
clinical signs of severe autoimmune neuroinflammation were observed.
Conclusions: Altogether, these results suggest that Aβ-specific CD8+ T cells are not major contributors to
meningoencephalitis in response to Aβ vaccination.
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Alzheimer’s disease (AD) is a severe neurodegenerative
disorder characterized by progressive loss of memory and
cognitive functions. Accumulation of amyloid-β peptide
(Aβ), both as soluble oligomers and in the form of amyloid
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unless otherwise stated.cascade in AD. Induction of specific adaptive immune re-
sponses following vaccination against Aβ1-42 was re-
ported to be of benefit in animal models of AD [1–3].
Antibodies to Aβ1-42 were proved efficient in clearing
amyloid plaques and in attenuating pathology in mouse
models of the disease [4, 5]. In line with these encouraging
results, clinical vaccination trial (AN1792) was initiated
and, although modest beneficial effects were observed in a
cohort of Aβ1-42-immunized AD patients, 6 % of them
developed meningoencephalitis [6]. Postmortem neuro-
pathological examination carried out in few Aβ-vaccinated
patients who developed such severe side effects revealedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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extensive macrophage infiltration and a reduction in amy-
loid burden [7, 8]. Second-generation immunotherapy
trials that rely exclusively on Aβ-specific antibodies were
then initiated, based either on the intravenous infusion of
humanized anti-Aβ monoclonal antibodies (mAbs) or vac-
cination strategies using the N-terminal portion of Aβ to
elicit antibodies without inducing Aβ-specific T cell re-
sponses. Among these strategies, trials with bapineu-
zumab [9, 10] and solanezumab [11] were the most
advanced, but results of phase 3 studies released in sum-
mer 2012 indicated that both antibodies were inefficient at
improving cognitive performance in AD patients. Failure
of these trials underlined the need for readdressing the
therapeutic capability of antibodies alone, and the role of
T cells in the therapeutic effect and/or meningoence-
phalitis observed in initial immunization studies based on
vaccination with full-length Aβ.
Increased T cell reactivity to Aβ has been observed in
the blood of elderly subjects and patients with AD, and
various Aβ-derived HLA class II-restricted CD4+ T cell
epitopes have been described [12]. Different HLA-DR
alleles were shown to impact Aβ immunogenicity in
humans and were associated with Aβ-specific T cell
responses to distinct T cell epitopes within residues 15–42
of Aβ [13]. Aβ-derived epitopes eliciting CD4+ T cell
responses have also been identified in different mouse
haplotypes and HLA class II transgenic mice [14–17].
Immunization of F1 SJLxB6 amyloid precursor protein
(APP) transgenic (APP-Tg) AD mice with dominant T cell
epitope Aβ10-24 stimulated peripheral CD4+ T cell
responses but did not result in T cell infiltration nor the
occurrence of meningoencephalitis. However, enhanced
expression of IFNγ in the brain of APP-Tg mice promotes
T cell infiltration targeted primarily to the sites of Aβ
deposition and was associated with both clearance of
Aβ and transient encephalitis upon immunization with
Aβ10-24, in the absence of antibodies to Aβ [18].
Altogether, these reports suggest that the magnitude of
Aβ-specific CD4+ T cell responses critically depends on
the nature of Aβ-derived T cell epitopes, which signifi-
cantly vary with MHC genotype. Thus, inappropriate
boosting of endogenous naturally occurring Aβ-specific
CD4+ T cell responses, e.g. through vaccination in the
presence of a Th1 adjuvant, may likely be involved in
the development of meningoencephalitis in selected
AN1792 patients displaying given MHC haplotypes.
Besides CD4+ T cell responses to Aβ, vaccination with
full-length Aβ1-42 may also activate Aβ-specific CD8+ T
cells. The characterization of such potentially autoreactive
CD8+ T cells has received little attention, presumably
because of their expected implication in the direct killing
of CNS cells and thus reduced therapeutic interest [19]. It
was previously reported that vaccination of BALB/c micewith Aβ-encoding DNA elicited IFNγ secretion by spleno-
cytes upon in vitro stimulation with Aβ12-28 but not
Aβ10-20, suggesting that a dominant immunogenic
epitope lies within amino acids 21 through 28. Reduction
of IFNγ secretion upon depletion of CD8+ T cells identi-
fied the phenotype of these effectors [15]. Nevertheless,
the potential impact of such MHC-I-restricted Aβ-specific
T cell responses on disease evolution and the develop-
ment of meningoencephalitis upon immunization re-
mains unknown.
In order to evaluate the role of Aβ-specific CD8+ T
cells in a mouse model of AD, we aimed at identifying
MHC class I-restricted Aβ-derived epitopes able to re-
cruit functional CD8+ T cell responses in C57BL/6 mice.
Vaccination with such epitopes in the absence of con-
comitant Aβ-specific humoral nor CD4+ T cell responses
was used to analyze the migration of CD8+ T cells into
the brain parenchyma of APPPS1 mice, and their poten-
tial role in the induction of meningoencephalitis and/or
neuronal damage. We identified one H-2-Db-restricted
naturally processed peptide, Aβ33-41, which elicits Aβ-
specific IFNγ-secreting CD8+ T cells displaying in vitro
cytotoxic activity towards Aβ-expressing targets. Aβ33-
41 was naturally processed and presented by CD11b+
microglia in the brain of APPPS1 but not WT mice.
Despite peripheral activation of functional Aβ-specific
CD8+ effectors and enhanced CD8+ T cell infiltration
into the brain parenchyma of APPPS1 mice immunized
with anchor-optimized Aβ33-41NP, no clinical signs of
autoimmune neuroinflammation were observed.
Methods
Mice and ethics statement
C57BL/6 mice (H-2b haplotype) were purchased from
Elevage Janvier (Le Genest Saint Isle, France). HLA-
A02.01/HLA-DR1-transgenic, H-2b class I-/II-knockout
mice [20, 21] on the C57BL/B6 background were kindly
provided by Pr François Lemonnier (Paris, France) and
were bred in our animal facility. APPPS1 double transgenic
mice (Thy1-APPKM670/671NL; Thy1-PS1L166P) which overex-
press mutated human APP and presenilin 1 genes on the
C57BL/6 background were kindly provided by Pr. Mathias
Jucker (Tubingen, Germany) [22]. Animals were bred and
maintained under strictly monitored specific and opportu-
nistic pathogen-free conditions. All experimental protocols
were conducted in accordance with good practices on the
care and use of laboratory animals, as defined by the rele-
vant national and/or local animal welfare bodies. Animal
studies were approved by the ethics committee of the Alfort
School of Veterinary Medicine.
Plasmids and peptides
A pcDNA3.1 vector encoding the human APP sequence
was used for DNA vaccination as already described [23].
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mer peptide sequence bearing H-2-Db-binding motifs
were selected by applying the epitope prediction algo-
rithm BIMAS (www-bimas.cit.nih.gov/) to human APP
amino acid sequence. Amino acids were substituted at
anchor positions for H-2-Db binding (positions 1, 2, 3, 5,
and 9) [24] by amino acids from a high binding affinity
peptide from the influenza nucleoprotein (NP366).
Modified peptides were mentioned as NP peptides.
Native and modified peptides (purity >90 %) were pur-
chased from GeneCust (Dudelange, Luxembourg). Hu-
man Aβ1-42 peptide was dissolved at 40 mg/ml in
DMSO and stored at −20 °C. Panel of Aβ-derived 9-mer
peptides overlapping by three amino acids were dis-
solved at 3 mM in DMSO, before final dilution in RPMI
medium for in vitro T cell stimulation.
Immunization protocols
For DNA vaccination, mice received two or three intra-
muscular injections of 100 μg of APP-pcDNA at weekly
interval [24]. These mice were sensitized 5 days before
with 50 μg cardiotoxin. For Aβ peptide immunization,
6- to 8-week-old mice were immunized by footpad
injections with 100 μg of Aβ1-42 emulsified in an equal
volume of CFA. In some experiments, mice were
boosted with 60 μg of Aβ1-42 emulsified in an equal
volume of IFA. When indicated, mice were injected sc
at the base of the tail with 100 μg of peptide, 50 μM of
oligo-CpG (N°3678), and 100 μg of the I-Ab-binding
hepatitis B virus (HBV) core peptide emulsified in an
equal volume of IFA.
Measurement of relative affinity of peptides for H-2-Db
RMAS lymphoma cells are deficient for TAP molecules
in charge of endogenous peptide transport and thus
express empty and unstable MHC class I molecules. To
evaluate the capacity of peptides to bind and stabilize
H-2-Db molecules, RMAS cells were incubated for 4 h
at 27 °C with various concentrations of peptides. Cells
were then washed and cultured for an additional 4-h
period at 37 °C in complete culture medium without pep-
tides. For staining, 2 × 105 peptide-loaded RMAS cells
were incubated for 20 min at 4 °C with biotin-conjugated
H-2-Db-specific mAb (clone 28-14-8, BD Biosciences,
Le Pont-de-Claix, France), followed by phycoerythrin-
conjugated streptavidin. Samples were analyzed with a
FACSCalibur (BD) flow cytometer, and data were pro-
cessed using the FlowJo software (Tree star, San Carlos,
CA, USA). Cell-surface fluorescence was expressed as
mean fluorescence intensity (MFI).
Anti-Aβ antibodies measurement by ELISA
To measure serum anti-Aβ antibody titers in immunized
mice, flat-bottom Nunc MaxiSorp ELISA plates werecoated overnight at 4 °C with Aβ1-42 peptide (1 μg/ml
in 0.1 M NaHCO3, pH 8.3). Plates were then washed
twice with PBS-T and blocked with PBS-1 % BSA for 2 h
at room temperature (RT). After two washes, plates were
incubated for 2 h at RT with serum samples at various
dilutions in blocking buffer. The Aβ1-17-specific mAb
6E10 (0.01 and 1 μg/ml) (Sigma-Aldrich, St Quentin
Fallavier, France) was used as a positive internal reference
sample. Plates were washed and incubated 90 min at RT
with peroxidase-conjugated goat anti-mouse IgG Ab
(Amersham, Little Chalfont, UK) and then revealed with
O-phenylenediamine/H2O2 substrate (Sigma-Aldrich). Re-
sults were expressed as relative OD = Experimental OD/
Reference OD for 6E10 mAb in the same plate.
FACS analysis
Single-cell suspensions were prepared from the spleens
and incubated for 15 min with anti-Fc receptor blocking
Ab (2.4G2, BD Biosciences, Franklin Lakes, NJ, USA) to
avoid non-specific staining. FITC-conjugated anti-CD4
(L3T4), APC-conjugated anti-CD8 (clone 53-6-7), and
PE-conjugated anti-CD19 (clone 1D3) mAbs (all from
BD Biosciences) were used for cell-surface staining.
Stained cells were analyzed using a FACSCalibur flow
cytometer, and data were processed using FlowJo.
Isolation of adult microglial cells
Brains were dissected, finely minced, and incubated in
5 ml PBS-1X 0.5 % BSA with 0.2 mg/ml Collagenase
IV (Roche, France) and 0.5 mg/ml DNase I (Sigma) for
35 min at 37 °C and 5 % CO2. After incubation, EDTA
(10 mM) was added to the suspension and tissue was
mechanically disrupted gently and cell suspensions
were passed through a 70-μm cell strainer. Cells were
then washed with PBS-1X 0.5 % BSA, resuspended in
4 ml of 30 % percoll solution and transferred into a
15-ml tube. Four ml of 37 % percoll was then added
below the cell suspension, followed by 4 ml of 70 %
percoll under the previous 37 % layer. Cells were then
centrifuged at RT for 40 min at 800 g, supernatant
containing the myelin was removed, and interphase layer
of mononuclear cells was harvested. Cells were washed
with PBS-1X 0.5 % BSA, and microglial cells were further
purified using anti-CD11b MicroBeads (Miltenyi Biotec,
Paris, France), according to manufacturer’s instructions.
Purity of isolated CD11b+ cells was >90 %, as verified by
flow cytometry.
ELISPOT assay
Nitrocellulose-based 96-well plates (Millipore, Billerica,
MA, USA) were coated with anti-mouse IFN-γ capture
mAb (1 μg/ml; clone R4-6A2, BD Biosciences) and satu-
rated with complete culture medium. Responder spleno-
cytes from individual mice were seeded at 106 or 5 × 105
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10 μg/ml of peptide. In some experiments, splenocytes
were stimulated with CD11b+ microglia (3 × 104/wells)
isolated from the brain of WT or APPPS1 mice, or with
mitomycin-treated 1C11 cells (2 × 104/wells), a neu-
ronal cell line expressing both APP and H-2b MHC-I
but not MHC-II molecules [25, 26]. Plates were incu-
bated at 37 °C in 5 % CO2 for 18 h, washed, and incu-
bated with biotinylated anti-mouse IFNγ detection mAb
(0.5 μ/ml; clone XMG1.2, BD Biosciences). Alkaline
phosphatase conjugated to streptavidin (Roche, France)
(1/500 dilution, 100 μL/well) was then added. IFNγ-
secreting cells were visualized using TNB/BCIP sub-
strate (Promega, Charbonnières, France), and spots were
counted using an automatic ELISPOT plate reader. Sam-
ples were assayed in triplicate, and the frequency of
peptide-specific T cells was calculated after subtracting the
mean number of spots obtained in the absence of peptide
or cells.In vitro 51Cr release cytotoxicity assay
Spleen cells (5 × 106 cells/ml) from immunized mice were
cultured at 37 °C with the matching NP peptide in
complete medium for 5 days. RMAS or 1C11 target cells
were labeled with 51Cr for 1 h at 37 °C, followed by exten-
sive washes. 105 51Cr-labeled RMAS cells/wells were then
incubated with matching NP peptides (10 μg/ml) for 2 h
in triplicate in 96-well round-bottom plates. Immune
effectors were then added at various E:T ratios. Alter-
natively, 2 × 104 51Cr-labeled 1C11 cells/wells were
incubated with immune effectors at various E:T ratios.
Culture supernatants were collected 4 h later, and 51Cr
release (cpm) was measured in a γ counter (LKB,
Orsay, France). The percentage of cytotoxicity was cal-
culated as follows: [1- (experimental release–minimum
release/maximum release–minimum release)] × 100,
where minimum release was the amount of 51Cr re-
leased by target cells without effectors, and maximum
release was the total amount of 51Cr obtained after lysis
of 105 RMAS or 2 × 104 1C11 cells.Monitoring the percentage of peptide-specific
CD8+ T cells in immunized mice
Blood was collected at different time points after vacci-
nation, and RBC were lysed. The frequency of 23-31NP-
and 33-41NP-specific CD8+ T cells was assessed by
intracellular IFNγ staining of CD8+ cells after 4 h of
incubation with either medium alone or with the native
or NP peptides, in the presence of brefeldin A (Cytofix/
Cytoperm Plus Golgi Plug Kit, BD Biosciences). The
percentage of IFNγ+ cells among CD8+ lymphocytes was
evaluated by FACS.Immunohistochemistry analyses
Brains collected at different disease stages were frozen in
OCT compound (VWR, Leuven, Belgium). The 5-μm
cryosections were prepared using a Leica RM2145
microtome and labeled with rabbit anti-mouse CD3
mAb revealed with Alexa Fluor 488-conjugated goat
anti-rabbit (Life Technologies), in combination with rat
anti-mouse CD8 mAb (Relia Tech Gmb, Braunschweig,
Germany) revealed with Alexa Fluor 594-conjugated goat
anti-rat mAb. Mononuclear phagocytes were detected
using a rat anti-mouse CD11b mAb (eBiosciences, Paris,
France) revealed with Alexa Fluor 488-conjugated goat
anti-rat mAb. At least three nonadjacent sections from
the midbrain area were analyzed, and Dapi-positive
stained cells were counted. Numbers were normalized
according to the tissue section surface area calculated by
the ImageJ software, and three mice per treatment were
examined. Amount of hAβ deposition was evaluated using
mouse anti-human Aβ mAb (BAM10, Sigma-Aldrich)
revealed with Alexa Fluor 594-conjugated goat anti-
mouse mAb.
Statistical analyses
Statistical analyses were carried out with Graphpad
Prism software (San Diego, CA, USA), using the
Mann–Whitney U test.
Results
Humanized HLA-A2.1/HLA-DR1 mice do not constitute an
appropriate model for assessing Aβ-specific CD8+ T cell
responses
Since T cell reactivity is strongly modulated by MHC
genotype, we first examined whether Aβ1-42 comprises
epitopes able to bind human MHC-I molecules. In silico
analysis of binding affinities for a large number of MHC
class I alleles (29 HLA-A or -B) of Aβ1-42-derived
candidate nonamer peptides was carried out using
BioInformatics and Molecular Analysis Section (BIMAS)
predictive algorithm. Whereas a large proportion of
alleles did not bind any Aβ-derived nonamer, about 30 %
of tested alleles bound potential Aβ-derived epitopes
with an affinity ranging from high to moderate (Table 1).
Among these, HLA-A2.01 was found to potentially bind
Aβ16-24 (BIMAS score: 453) and Aβ33-41 (BIMAS
score: 15). These data indicate that Aβ can potentially
promote the development of CD8+ T cell responses in
selected MHC haplotypes. To assess this hypothesis,
HLA-A2.1/HLA-DR1/H-2b−/− double Tg mice on the
C57BL/6 background (19–20) were immunized with Aβ/
CpG/IFA. Analysis of splenocytes 14 days later showed
that only CD4+ T cells that secrete IFNγ responded to
Aβ1-42 immunization and recognized an immunodomi-
nant epitope located between amino acids 1–18 (Fig. 1a).
Of note, Aβ28-42 15-mer candidate peptide could not
Table 1 Epitope prediction by BIMAS algorithm: estimated binding
affinities of Aβ-derived nonamers to various HLA molecules
HLA molecule Start AA position Nonamer peptide BIMAS scorea
A1 20 VFFAEDVGS 18
A02.01 16 KLVFFAEDV 453
33 GLMVGGVVI 15
A02.05 31 IIGLMVGGV 6
A24 9 GYEVHHQKL 396
A3 16 KLVFFAEDV 2
A11.01 - - -
A31.01 - - -
A33.02 7 DSGYEVHHQ 1.5
A68.01 24 VGSNKGAII 24
B14 4 FRHDSGYEV 4
B27.02 4 FRHDSGYEV 20
2 AEFRHDSGY 15




B28.01 - - -
B35.01 26 SNKGAIIGL 3
B37.01 - - -
B38.01 12 VHHQKLVFF 30
B39.01 - - -
B39.02 27 NKGAIIGLM 12
B40 2 AEFRHDSGY 32
10 YEVHHQKLV 16
B44.03 2 AEFRHDSGY 240
B51.01 24 VGSNKGAII 104
32 IGLMVGGVV 57
28 KGAIIGLMV 24
B51.02 33 GLMVGGVVI 132
24 VGSNKGAII 88
28 KGAIIGLMV 28
B51.03 32 IGLMVGGVV 52
24 VGSNKGAII 48
28 KGAIIGLMV 40
B52.01 32 IGLMVGGVV 300
24 VGSNKGAII 75
28 KGAIIGLMV 36
B62 32 IGLMVGGVV 5
B7 26 SNKGAIIGL 4
B8 26 SNKGAIIGL 4
aEstimated half time of dissociation of corresponding MHC/peptide complexes,
using BIMAS algorithm. Values above significant affinity threshold are depicted
in italic
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hydrophobicity and poor solubility. Although we cannot
rule out that such peptide may include a poten-
tial MHC-II-restricted epitope, its biochemical features
make unlikely the efficient MHC binding and presenta-
tion of Aβ28-42. Moreover, Aβ-specific antibodies were
detected by ELISA in the serum of immunized mice
(Fig. 1b). However, this immunization procedure did not
trigger any CD8+ T cells able to recognize dendritic cells
loaded with either Aβ or overlapping nonamer peptides
covering the entire Aβ sequence (data not shown).
The two HLA-A2.01-restricted Aβ-derived epitopes,
Aβ16-24 and Aβ33-41, were then mixed with a 14-mer
human CD4+ helper epitope (Padre) in CpG/IFA and
used for sc immunization in HLA-A2.1/HLA-DR1 mice.
Padre (pan-DR epitope) was used in all experiments
using HLA-DR transgenic mice, based on its very high
MHC-II binding and helper activity [27]. The number of
IFNγ-secreting splenocytes was high in response to the
Aβ-unrelated CD4+ helper epitope but weak or null in
response to the corresponding Aβ-derived nonamer
CD8+ peptides (Fig. 2a). Phenotypic analysis revealed
that the percentage of CD4+ and CD8+ T cells was twice
lower in the spleen of untreated HLA-A.2.1/HLA-DR1
mice (7.8 and 4.9 %, respectively) than in regular
C57BL/6 mice (16.4 and 10.4 %, respectively; p = 0.0003)
(Fig. 2b). Such altered basal numbers of CD8+ T cells
may contribute to the weak functional CD8+ T cell
responses to Aβ vaccination in this mouse model.
Altogether, these data suggest that Aβ-specific CD8+ T
cell responses cannot be efficiently triggered in huma-
nized HLA-A2.1/HLA-DR1/H-2b−/− mice.Aβ-specific CD8+ T cells can be triggered in C57BL/6 mice
by anchor-modified peptides
In order to appropriately address the impact of Aβ-
specific CD8+ T cell responses in vivo, we aimed at identi-
fying Aβ-derived epitopes able to trigger specific CD8+ T
cells in regular C57BL/6 mice (H-2b). Mice were immu-
nized with Aβ/CpG/IFA, and splenocytes were analyzed
14 days later for the presence of Aβ-specific T cells.
Although splenocytes secreted IFNγ in response to full-
length Aβ1-42, none of the 12 overlapping Aβ-derived
nonamer peptides reactivated effector cells (Fig. 3a). Anti-
bodies specific for Aβ1-42 were detected in the serum of
immunized mice (Fig. 3b) and were predominantly of
IgG1 and IgG2b isotypes, suggesting the development of a
Th2 type immune response (Fig. 3c). Of note, attempts to
generate Aβ-specific CD8+ T cell responses using APP-
encoding DNA also failed (data not shown). These results
suggest that vaccination with full-length Aβ can efficiently
elicit CD4+ but not CD8+ T cell responses in the H-2b
mouse haplotype, suggesting the poor immunogenicity of
Fig. 1 Aβ-specific CD4+ T cells and antibodies but not CD8+ T cells are triggered in HLA-A2.1/HLA-DR1 mice upon Aβ vaccination. (a) Frequency
of IFN-γ secreting splenocytes in Aβ-immunized HLA-A2.1/HLA-DR1 mice, as assessed by ELISPOT. Splenocytes (106/wells) from mice immunized
with either PBS/CpG/IFA or Aβ1-42 in CpG/IFA were stimulated in triplicate for 18 h at 37 °C with Aβ1-42 (40 μg/ml) or 15-mer overlapping peptides
(10 μg/ml) covering the full length of Aβ1-42. Results are presented as numbers of peptide-specific IFNγ-secreting cells per 106 splenocytes, calculated after
subtracting the mean number of spots obtained in the absence of peptide. (b) Serum levels of Aβ-specific antibodies were measured by ELISA using
Aβ-coated plates. Data are expressed as relative OD. Mean ± SD (two to four mice/group). Results are representative of two independent experiments
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this MHC context.
BIMAS predictive algorithm was used to identify Aβ-
derived nonamer peptides bearing MHC-I-binding mo-
tifs in H-2b haplotype. Two peptides were found to bind
H-2-Db molecules with moderate (Aβ23-31, score 45) and
low (Aβ33-41, score 4) theoretical affinities (Table 2), and
none were found to bind H-2-Kb molecules.
The candidate peptides were synthesized, and their
actual affinity was determined by measuring their capacityFig. 2 Immune responses of HLA-A2.1/HLA-DR1 mice after
immunization with Aβ-derived CD8+ candidate epitopes. (a) Frequency
of IFNγ-secreting splenocytes in peptide-immunized mice, as assessed
by ELISPOT. Spleen cells (106/wells) from mice immunized with either
Aβ16-24 or Aβ33-41 in CpG/Padre/IFA or with PBS/CpG/Padre/IFA
were stimulated in triplicate for 18 h at 37 °C with the immunizing
peptide or Padre CD4+ helper peptide (10 μg/ml). Results are
presented as numbers of peptide-specific IFN-γ-secreting cells per 106
splenocytes, calculated after subtracting the mean number of spots
obtained in the absence of peptide. (b) Phenotypic analysis of C57BL/6
wt and HLA-A2.1/HLA-DR1 mice. Percentage of splenocytes positive for
CD4, CD8, and CD19 markers as measured by FACS. Mean ± SD
(two to four mice/group). Results are representative of two
independent experiments. Mann–Whitney U test, *p ≤ 0.05,
**p ≤ 0.01to bind and stabilize H-2-Db molecules on the cell surface
of RMAS cells. Incubation with various peptide concen-
trations weakly stabilized MHC class I expression as com-
pared to incubation with a reference peptide of high
affinity (Influenza virus nucleoprotein, NP366, score 286)
(Fig. 4a). To increase binding affinities of Aβ23-31 and
Aβ33-41, amino acids at H-2-Db anchor positions (P1, P2,
P3, P5, and P9) were substituted by those of the high-
affinity peptide NP366 (Table 2; NP peptides). These
modifications highly increased the theoretical affinities of
the two peptides (Aβ23-31NP, score 286; Aβ33-41NP,
score 343) for H-2-Db molecules and lead to MHC class I
stabilization on RMAS cells to a similar level than with
NP366 reference peptide (Fig. 4a).
C57BL/6 mice were immunized with native or NP-
modified epitopes mixed with a 14-mer CD4+ helper
peptide (I-Ab-restricted murine epitope, HBV core) in
CpG/IFA. The frequency of CD8+ T cells specific for the
native or NP peptides was first evaluated in the blood by
intracellular IFNγ staining assay. In vitro restimulation
for 4 h with native peptides did not result in enhanced
percentages of peripheral CD8+IFNγ+ cells in any groups
of treated mice (Fig. 4b). In contrast, upon in vitro
restimulation with the immunizing NP peptide, mice
immunized with 33-41NP displayed significantly higher
percentages of CD8+IFNγ+ cells than mice receiving CpG
alone (1.78±0.19 versus 0.57±0.11, respectively, p = 0.01).
Of note, no IFNγ+ cells were observed in CD8− lympho-
cytes, confirming that 33-41NP selectively triggers CD8+
and not CD4+ T cell responses (data not shown).
Frequency of CD8+IFNγ+ cells was not consistently
enhanced in the blood of 23-31NP-immunized mice,
although two mice out of five had a detectable IFNγ
Fig. 3 Analysis of Aβ-specific immune responses in regular C57BL/6 mice upon vaccination with Aβ1-42. (a) Frequency of Aβ-specific IFNγ-producing
splenocytes in immunized mice, as assessed by ELISPOT. Spleen cells (106/wells) from mice immunized with either PBS/CpG/IFA or Aβ1-42 in CpG/IFA
were restimulated in triplicate for 18 h with Aβ1-42 (40 μg/ml) or a panel of overlapping nonamer peptides (10 μg/ml) covering the full length of
Aβ1-42. Results are presented as numbers of peptide-specific IFNγ-secreting cells per 106 splenocytes, calculated after subtracting the mean number of
spots obtained in the absence of peptide. (b, c) Aβ-specific antibody responses in Aβ1-42-immunized mice. Levels of anti-Aβ antibodies in the sera
were determined by ELISA using Aβ-coated plates. Data are expressed as relative OD. Mean ± SD (two to four mice/group). Results are representative
of two independent experiments
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vaccine-induced immune responses was also measured by
ELISPOT assay 14 days post immunization. Results indi-
cated that splenocytes from 33-41NP-immunized mice
but not splenocytes from mice immunized with the 33–41
native peptide significantly (p < 0.01) secreted IFNγ in
response to the NP-modified but not to the native peptide.
Notably, 33-41NP-specific splenocytes also did not
respond to the NP366 peptide, confirming that they were
specific for TCR-exposed residues from Aβ33-41 (Fig. 4c).
In contrast, the number of IFNγ-secreting splenocytes was
not significantly enhanced in mice immunized with either
Aβ23-31 or Aβ23-31NP (Fig. 4c). IFNγ-producing cells
were also detected in splenocytes from 33-41NP-
immunized mice upon restimulation with 1C11 neuronal
cells, which express both APP and H-2b MHC-I but
not MHC-II molecules (Fig. 4c). Similar results were
obtained with 1C11 cells when using CD8+ T cells
purified from 33-41NP-immunized splenocytes (data
not shown). Importantly, splenocytes from 33-41NP-Table 2 Sequence and binding affinity of Aβ-derived
H-2-Db-restricted candidate epitopes
Peptides Amino acid sequences BIMAS scorea
Aβ23-31 D V G S N K G A I 45
23-31NP A S N S N K G A M 286
Aβ33-41 G L M V G G V V I 4
33-41NP A S N V N G V V M 343
NP366 A S N E N M D A M 286
Amino acid sequence of nonamer peptides derived from Aβ using the BIMAS
prediction algorithm. Aβ peptides were modified (NP peptides) by replacing
amino acids at the H-2-Db anchor sites (depicted in italic) by amino acids from
a high-binding affinity peptide (influenza virus nucleoprotein NP366)
aEstimated half time of dissociation of H-2-Db/peptide complexes, using
BIMAS algorithmimmunized mice significantly (p < 0.01) secreted IFNγ
in response to brain-derived CD11b+ microglial cells
isolated from APPPS1 mice but not from WT animals
(Fig. 4d). Altogether, these results indicate that Aβ33-
41 epitope can be naturally processed and presented
in both microglia and neuronal cells, and that 33-41NP
peptide efficiently stimulates an Aβ-specific CD8+ T cell
repertoire in C57BL/6 mice.
We next analyzed the cytolytic activity of splenocytes
from NP-peptide-immunized mice. After a 5-day in vitro
restimulation in the presence of 23-31NP or 33-41NP,
cytotoxic activity towards 51Cr-labeled peptide-loaded
RMAS cells or 1C11 neuronal cells was evaluated.
Immune effectors specific for 23-31NP or 33-41NP were
able to lyse RMAS targets loaded with the matching NP
peptides (50.7 and 65.9 % lysis, respectively; E:T ratio
1:50) (Fig. 5a). However, only splenocytes from 33-41NP-
immunized mice moderately lysed (23.3 %) 1C11 cells
(Fig. 5b). Thus, we identified one epitope, Aβ33-41, which
is restricted to H-2-Db MHC class I molecule and is
naturally processed in both microglia and neuronal cells.
When anchor optimized, modified Aβ33-41 peptide can
elicit anti-Aβ CD8+ T cell responses that display cytotoxic
activity towards Aβ-expressing neuronal target cells.
Aβ33-41NP activates specific CD8+ T cells in APPPS1
mouse model of AD
The H-2-Db-restricted Aβ-derived epitopes we identified
were used to elicit Aβ-specific cytotoxic CD8+ T cell
responses in the C57BL/6-based APPPS1 mouse model
of AD [22]. APPPS1 mice and WT littermates were
immunized between the age of 4 to 7 months with
23-31NP or 33-41NP mixed with CD4+ helper peptide
(HBV core) in CpG/IFA. The frequency of peptide-
Fig. 4 Binding affinities and immunogenicity of Aβ-derived CD8+ candidate epitopes. (a) RMAS cells were incubated with indicated concentrations of
native or NP-modified peptides, and cell surface stabilization of H-2-Db was evaluated by FACS. Data are presented as mean fluorescence intensity
(MFI) of H-2-Db staining. NP366 served as a high-affinity reference peptide. (b) Frequency of IFNγ-producing specific CD8+ T cells in the blood
of immunized mice. C57BL/6 mice were vaccinated with NP-modified peptides in CpG/HBV/IFA or with PBS/CpG/HBV/IFA, and animals were
bled 14 days later. Percentage of peptide-specific T cells among CD8+ cells in the blood was determined by intracellular IFNγ staining after
in vitro restimulation. (c, d) Frequency of Aβ-specific IFNγ-producing splenocytes in immunized mice, as assessed by ELISPOT. (C) C57BL/6
mice were immunized with PBS/CpG/HBV/IFA or the indicated peptides in CpG/HBV/IFA, and 14 days later, spleen cells (106/wells) were
restimulated for 18 h with either the matching native or NP peptide, the HBV-derived helper peptide, or NP366 (10 μg/ml). For immunization with
PBS/CpG/HBV/IFA, splenocytes were restimulated with each of the native or NP peptides and data were expressed as mean of the two values.
Splenocytes were also stimulated with mitomycin-treated 1C11 cells (2 × 104/wells), a neuronal cell line expressing both APP and H-2b MHC-I.
Results are presented as numbers of IFN-γ-secreting cells per 106 splenocytes, after subtracting the mean number of spots obtained in the
absence of peptide or cells. (D) Splenocytes (2 × 105/wells) of C57BL/6 mice previously immunized with either PBS/CpG/HBV/IFA or 33-41NP
mixed in CpG/HBV/IFA were restimulated on day 14 with 33-41NP (10 μg/ml) or CD11b+ microglia (3 × 104/wells) isolated from the brain of
WT or APPPS1 mice. Mean ± SEM (three to four mice/group). Results are representative of two independent experiments. Mann–Whitney
U test, *p ≤ 0.05, **p ≤ 0.01
Fig. 5 Immunization of C57BL/6 mice with NP peptides triggers specific and functional cytotoxic cells. Spleen cells from mice immunized with
PBS/CpG/HBV/IFA or with the indicated NP peptides mixed in CpG/HBV/IFA were restimulated for 5 days with matching NP peptides (10 μg/ml).
In the case of immunization with PBS/CpG/HBV/IFA, splenocytes were restimulated with each of the NP peptides. Various concentrations of immune
effectors specific for 23-31NP or 33-41NP were incubated for 4 h in the presence of 51Cr-labeled peptide-loaded RMAS cells (105 cells/wells) or of
51Cr-labeled 1C11 cells (2 × 104/wells). In the case of immunization with PBS/CpG/HBV/IFA, splenocytes were incubated with one or the other
peptide-loaded RMAS cells or medium alone. Results are reported as the percentage of cytotoxicity calculated as described in Methods
section. Results are representative of two independent experiments
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days post immunization. Results depicted in Fig. 6a
show that a significant percentage of CD8+IFNγ+ cells
was observed in the blood of both APPPS1 and WT
mice immunized with 33-41NP (p < 0.01) but not in
23-31NP-immunized mice, compared to mice receiving
only CpG. Whereas such responses were observed upon
in vitro restimulation with NP peptides, only low and
non-significant responses were detected after restimu-
lation with the native peptides. ELISPOT assay further
showed that immunization with 33-41NP but not with
23-31NP was able to elicit in vivo Aβ-specific IFNγ-
secreting splenocytes in both APPPS1 mice and WT
littermates. These cells recognized in vitro the matching
NP peptide or the endogenously processed epitope in
1C11 neuronal cells but did not recognize the native
peptide when loaded exogenously (Fig. 6b). Of note,
immunized APPPS1 and WT mice similarly responded
to the Aβ-unrelated CD4+ helper epitope. These results
confirm that Aβ33-41NP was able to activate peripheral
Aβ-specific CD8+ T cells in APPPS1 mice.
Aβ33-41NP specifically promotes CD8+ T cell infiltration
into the brain of APPPS1 mice without triggering
encephalitis
The magnitude of T cell infiltration and CD11b immu-
noreactivity in the brain was evaluated as a function of
age in APPPS1 as compared to WT mice. Immunohisto-
chemistry analyses showed that the number of CD3+ TFig. 6 Analysis of Aβ-specific immune responses in APPPS1 mice upon
WT littermates were immunized with indicated native or NP-modified p
(a) Frequency of peptide-specific IFNγ-producing cells among CD8+ lym
by intracellular IFNγ staining after restimulation with the native or NP p
in immunized mice, as assessed by ELISPOT. Fourteen days after vaccin
18 h with either the matching native or NP peptide or with HBV-deriv
PBS/CpG/HBV/IFA, splenocytes were restimulated with each of the nativ
values obtained for each category of peptide (i.e., native or NP). Spleno
mitomycin-treated 1C11 cells (2 × 104/wells). Results are presented as n
after subtracting the mean number of spots obtained in the absence o
are representative of two independent experiments. Mann–Whitney Ucells significantly increased (p = 0.01) in the brain of
APPPS1 mice between 4 and 7 months of age. In con-
trast, only moderate T cell infiltration was observed with
aging in the brain of WT littermates (Fig. 7a, b). The
number of CD11b+ cells remains constant in the brain
of WT mice, whereas it significantly increases (p = 0.02)
between 4 and 7 months of age in APPPS1 mice (Fig. 7c, d),
in line with the described microgliosis associated with Aβ
deposition in this model [22]. The progressive accumula-
tion of CD3+ and CD11b+ cells in the brain of APPPS1
mice parallels the significant (p = 0.001) Aβ deposition
measured by ELISA (Fig. 7f). Of note, no differences in
the percentages of CD3+ cells were detected in the spleen
of APPPS1 and WT mice whatever the age (Fig. 7e). These
observations suggested that recruitment and/or local ac-
cumulation of CD3+ T cells and CD11b+ mononuclear
phagocytes in the brain of APPPS1 mice is related to dis-
ease development.
To evaluate if peripherally activated Aβ-specific CD8+ T
cells specifically infiltrate the brain upon vaccination,
APPPS1 and WT mice were immunized twice at 1-month
interval with either 33-41NP or 23-31NP as a control
peptide. Cells positive for CD3 and/or CD8 markers were
then quantified in the brain 2–3 weeks after the last
immunization. Higher numbers of CD3+ T cells previously
observed in the brain of untreated APPPS1 mice as com-
pared to age-matched WT littermates were related to an
increase in both CD8− (p = 0.018) and CD8+ (p = 0.04) T
cells. Importantly, CD8− cells always predominate overvaccination with Aβ-derived nonamer epitopes. APPPS1 mice or
eptides mixed in CpG/HBV/IFA or with PBS/CpG/HBV/IFA alone.
phocytes in the blood was determined 14 days after vaccination,
eptides. (b) Frequency of Aβ-specific IFNγ-secreting splenocytes
ation, spleen cells (106/wells) were restimulated in triplicate for
ed helper peptide (10 μg/ml). In the case of immunization with
e or NP peptides and data are expressed as the mean of the two
cytes from immunized mice were also stimulated in vitro with
umbers of IFN-γ-secreting cells per 106 splenocytes, calculated
f peptide or cells. Mean ± SD (three to four mice/group). Results
test, *p ≤ 0.05
Fig. 7 Comparative analysis of immune populations in APPPS1 and WT mice between 4 and 7 months of age. Representative images from brain
cortex of APPPS1 mice (a, c) and numbers of CD3+ T cells (b) or CD11b+ cells (d) in the brain parenchyma of WT and APPPS1 mice. (e) Percentage of
CD3+ T cells in the spleen analyzed by flow cytometry. (f) Quantification by ELISA of Aβ load in the brain. Mean ± SD (three to five mice/group).
Results are representative of two independent experiments. Mann–Whitney U test, **p ≤ 0.01, ***p ≤ 0.001
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A significantly enhanced infiltration (p < 0.01) of both
CD3+CD8− and CD3+CD8+ cells was detected into the
brain of WT mice following immunization with CpG +
CD4+ helper epitope, whether or not it was mixed withthe CD8+ peptides (Fig. 8b). In contrast, the number of
CD3+CD8+ cells selectively increased in the brain
parenchyma of APPPS1 mice after vaccination with
33-41NP (36.7+/−4.8; p = 0.057) but not with 23-31NP
(17.1+/−2.5) as compared to untreated animals (16.8+/−2.2)
Fig. 8 Aβ33-41NP specifically promotes CD8+ T cell infiltration into the brain of APPPS1 mice. Four-month-old APPPS1 mice or WT littermates
were immunized twice with 23-31NP or 33-41NP mixed in CpG/HBV/IFA, or treated with PBS/CpG/HBV/IFA alone. Brains were harvested between
6 and 7 month of age, and immune cell infiltration was analyzed by immunohistochemistry. Brain sections were stained with anti-CD3 + anti-CD8
mAbs or anti-CD11b mAb. (a) Representative images from brain cortex of control or 33-41NP-immunized APPPS1 mice. (b) Numbers of CD3+CD8− or
CD3+CD8+ cells per brain section. (c) CD8−/CD8+ ratio. (d) Percentage of CD8+ cells in the blood and spleen analyzed by flow cytometry. (e) Representative
images of CD11b labeling in the cortex of control or 33-41NP-immunized APPPS1 mice. (f) Numbers of CD11b+ cells per brain section. Mean ± SEM
(three to five mice/group). Results are representative of two independent experiments. Mann–Whitney U test, *p ≤ 0.05, **p ≤ 0.01
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the brain of APPPS1 mice immunized with 33-41NP
(18.6+/−2.6) and 23-31NP (17.3+/−3.7), although not sig-
nificantly as compared to untreated mice (27.0+/−3.2). Of
note, numbers of both CD3+CD8− and CD3+CD8+ cells
are slightly increased after CpG treatment alone. Analysis
of CD8−/CD8+ ratios confirmed that CD3+CD8− cells pre-
dominate over CD3+CD8+ cells into the brain in all immun-
izing conditions including CpG alone, except for APPPS1
mice immunized with 33-41NP (CD8−/CD8+ = 0.57)(Fig. 8c). No significant differences in the overall percen-
tage of CD8+ cells were observed in either the spleen or
blood of WT and APPPS1 mice after any type of immu-
nizations, suggesting a brain-restricted enhancement of
CD8+ T cell recruitment in 33-41NP-immunized APPPS1
mice (Fig. 8d).
Variations in the number of CD11b+ cells upon
immunization were also evaluated in the brain of WT
and APPPS1 mice (Fig. 8e, f ). In accordance with Aβ-
related microgliosis, untreated APPPS1 mice display
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mice. Of note, whereas immunization with CpG, 23-31NP,
or 33-41NP induced no modification in WT mice, it
significantly reduces (p < 0.01) the number of CD11b+
mononuclear phagocytes in the brain parenchyma of
APPPS1, leading to similar numbers as in age-matched
WT mice (Fig. 8e, f ).
Importantly, despite peripheral activation of Aβ-specific
CD8+ cytotoxic effectors and enhanced infiltration of
CD8+ T cells into the brain of Aβ33-41NP-immunized
APPPS1 mice, no clinical signs (e.g., kyphosis, paraplegia)
of severe autoimmune neuroinflammation were observed.
Altogether, these results suggest that vaccine-induced
Aβ33-41NP-specific CD8+ T cells preferentially and
selectively accumulate into the brain parenchyma of
APPPS1 mice at later disease stages associated with
increased Aβ deposition, without triggering encephalitis
nor severe brain damages.
Discussion
The development of meningoencephalitis in some AD
patients following Aβ vaccination (AN1792) was sought
to involve pro-inflammatory CD4+ T cells [7, 8]. In this
work, using mouse models, we address the possible
implication of auto-aggressive Aβ-specific CD8+ T cells
in the development of these severe side effects. In
contrast to MHC-II-restricted epitopes, the length of
peptides able to bind MHC-I molecules is precisely
determined by biochemical constraints. Consequently,
the array of potential MHC-I-restricted epitopes derived
from a small Ag like Aβ1-42 is rather limited, which
might explain why only 6 % of patients developed severe
adverse effects following Aβ vaccination [6]. In silico
analyses using BIMAS predictive algorithm suggested
that Aβ might give rise to MHC-I-restricted epitopes in
approximately 30 % of class I HLA alleles, including
HLA-A2.1 (Table 1). We first sought to validate in
HLA-Tg mice the capacity of such Aβ-derived epitopes
to recruit CD8+ T cell responses. Yet, HLA-A2.1/HLA-
DR1/H-2b−/− double transgenic mice on C57BL/6 back-
ground failed to develop a functional response after
immunization with Aβ16-24 candidate epitope, despite
its theoretical high binding affinity for HLA-A2.1. Lack
of CD8+ T cell response induction may result from
altered overall frequency of CD4+ and CD8+ T cells in
HLA-transgenic mice, lack of natural processing of this
HLA-A2.1-restricted Aβ-derived epitope, or deletion
of high-avidity T cells specific for dominant epitopes
derived from a self-antigen.
Similarly, no Aβ-specific CD8+ T cell response was
obtained in regular C57BL/6 mice upon vaccination with
Aβ. In contrast to our prediction studies for class I HLA
alleles, in silico predictive analyses revealed poor affini-
ties of Aβ-derived H-2-Db-restricted epitopes. A specificapproach aimed at optimizing the binding affinity and
immunogenicity of these MHC-I-restricted candidate
epitopes was thus required for accurately assessing the
impact of Aβ-specific CD8+ T cells in response to
vaccination. Optimized epitopes were engineered as pre-
viously described in various models [24, 28, 29]. Main
MHC-I anchor residues of candidate epitopes were sub-
stituted by anchor residues of the NP366 reference pep-
tide, which displays high affinity for H-2-Db, without
altering TCR contact residues. Importantly, T-cell
responses generated using such engineered epitopes
retained their specificity for the matching native
epitopes and did not recognize the reference peptide.
Immunization with two such anchor-optimized epi-
topes, Aβ33-41NP and Aβ23-31NP, activated CD8+
T cells that secrete IFNγ and are cytotoxic towards
peptide-loaded targets. However, only Aβ33-41 but not
Aβ23-31 appears to be naturally processed and pre-
sented to immune effectors by a neuronal cell line
expressing both APP and H-2b MHC-I molecules
[25, 26] as well as by brain-derived CD11b+ microglia
isolated from APPPS1 mice. Of note, although neuronal
cells, microglia, or other APCs such as dendritic cells
(data not shown) efficiently present the endogenous
peptide, Aβ33-41 native peptide could not restimulate
Aβ33-41NP-specific CD8+ T cells when loaded exoge-
nously. These data suggest that full endogenous machin-
ery for antigen processing and presentation, including
chaperone activities, is critically required for efficient pre-
sentation of potential low-affinity cryptic epitopes from
pathogenic antigens. In contrast, when provided exoge-
nously, such weak epitopes are likely very poorly efficient
at replacing antigenic peptides from pre-formed MHC/
peptide complexes at cell surface.
Immunization of APPPS1 mice with the anchor-
optimized Aβ33-41NP peptide efficiently stimulated Aβ-
specific CD8+ T cells in such C57BL/6-based mouse
model of AD. Importantly, similar numbers of IFNγ-
secreting CD8+ T cells were observed in the periphery of
both APPPS1 and WT littermates following vaccination,
ruling out an overall immunosuppressive environment
in the context of AD. Our study does not confirm pre-
vious reports suggesting that APP overexpression in
transgenic mice might be associated with impaired Aβ-
specific adaptive immunity [30]. In contrast, our data are
consistent with studies showing increased frequencies of
Aβ-reactive T cells in the blood of both healthy elderly
and patients with AD, as compared to younger healthy
adults [12].
Several studies reported that the brain is continuously
monitored by memory T cells, whereas only few naïve
CD3+ T cells gain access to the brain in healthy indi-
viduals [31]. We found that numbers of CD3+ T cells
significantly increase with age in the brain of APPPS1
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of both CD8− and CD8+ populations, with a predomin-
ance of CD8− over CD8+ cells. In the same line,
increased numbers of T cells have been described in the
brain parenchyma of AD patients, mostly in the hippo-
campus [32]. Importantly, inverted CD8−/CD8+ ratio
with a predominance of CD8+ over CD8− cells was
selectively observed in the brain of APPPS1 but not WT
mice after Aβ33-41NP immunization. These data sug-
gest that such intracerebral accumulation of CD8+ T
cells specifically occurs in the context of AD and de-
pends on specific antigen expression, as supported by
the capacity of brain-derived CD11b+ microglia from
APPPS1 but not from WT mice to activate Aβ33-
41NP-specific effectors. The preferential recruitment of
Aβ-specific CD8+ T cells into the brain parenchyma of
vaccinated APPPS1 mice is further supported by the
fact that 1) induction of CD8+ T cell responses specific
for Aβ23-31 peptide, which turned out not to be na-
turally processed, did not induce any change in the
CD8−/CD8+ ratio into the brain of APPPS1 mice; 2) no
modification in the overall percentages of CD4+ and
CD8+ T cells was observed in the blood and spleen of
APPPS1 mice after immunization. Altogether, these
results suggest that Aβ-specific CD8+ T cells triggered
by vaccination with anchor-modified epitope are speci-
fically recruited into the brain parenchyma of APPPS1
mice. A mechanism of Ag-dependent recruitment of
CD8+ T cells into the brain of EAE mice was previously
described [33]. Our results are in line with these studies
and suggest that Aβ-derived MHC-I-restricted epitopes
and particularly Aβ33-41 may efficiently be processed
and presented by cerebral vascular endothelial cells in
the brain of AD mice.
Strikingly, despite specific infiltration of the brain by
functional self-reactive CD8+ T cells and specific anti-
gen processing and presentation by both neuronal cells
and CD11b+ microglia, no clinical sign of autoimmune
neuroinflammation or CNS damages was observed in
Aβ33-41NP-immunized APPPS1 mice. In accordance
with our data, increased numbers of CD3+ cells in the
hippocampus of AD patients did not parallel activation
of microglia nor disease stages. T cells were found
negative for CD25 and the vast majority of them was
CD45RO+ but CR3−, indicating that they were activated
and potent cytokine producers but not fully differenti-
ated, possibly due to insufficient stimuli or immunosup-
pressive environment in the brain [32]. Weak expression
of MHC class I molecules on neurons [34] and/or their re-
sistance to perforin-mediated lysis by CTLs [35] may par-
tially account for such absence of detrimental effect of
infiltrating CD8+ T cells. In addition, the CNS parenchyma
was described to constitute a particular microenvironment
with potent immunoregulatory properties, especially inthe context of neuroinflammatory conditions such as AD.
Astrocytes, activated microglia, and neurons can express
several factors that negatively regulate T cell activation,
proliferation, and cytokine production [36]. Moreover, it
has been proposed that upon extravasation into the CNS,
T cells primed in the periphery need to be restimulated by
perivascular and/or meningeal APCs for being fully
licensed before accessing the brain parenchyma [37]. The
efficiency of these particular APCs at taking up Aβ and
cross-presenting Aβ-derived epitopes to CD8+ T cells
remains unknown and may also constitute a critical
parameter restraining the functionality of Aβ-specific CD8+
T cells inside the brain parenchyma. Finally, we cannot
rule out that altered behavior of infiltrating Aβ-specific
CD8+ T cells in such mouse models may rely on other
specific mechanisms related to migration and functional
regulation of T cells within the AD brain parenchyma,
which may significantly differ between mouse and human.
In this line, a critical role of IFNγ in the migration and
functional outcome of Aβ-specific CD4+ T cells in mouse
models of AD has previously been discussed [38]. Deci-
phering the overall impact of such parameters on both
CD4+ and CD8+ T cell responses in the context of the AD
brain definitely requires further analyses. Such studies
may hold the key for the development of refined mouse
models of AD with optimized disease-related immuno-
logical relevance, which are of paramount importance for
better understanding the pathophysiology of AD and for
accurately evaluating the efficiency and safety of innova-
tive immunotherapy approaches.
After both Aβ-specific or non-specific vaccination, the
high number of CD11b+ cells observed in the brain of
untreated APPPS1 mice was significantly reduced to
similar levels than in WT littermates. In line with recent
reports, these data suggest that modulation of peripheral
immunity and inflammatory status may significantly
impact the magnitude and/or shaping of parenchymal
neuroinflammation, including modifications in microglia
phenotype and activation profile [39, 40].
In conclusion, our results do not support a role for
Aβ-specific CD8+ T cells in the development of menin-
goencephalitis after Aβ immunization. Whereas func-
tional anti-Aβ CD8+ cytotoxic T cells can be peripherally
activated and specifically recruited to the brain, immune
ignorance or altered functionality of these effectors in
the microenvironment of the AD brain parenchyma may
be responsible for their lack of detrimental effect.
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